Fig. 4 | Signal Transduction and Targeted Therapy

Fig. 4

From: PRIME-HFrEF Trial: a randomized, double-blind, multi-dose umbilical cord-derived mesenchymal stem cell regimen for heart failure

Fig. 4

Left ventricular function and dimensions. Changes (Δ) in left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), and left ventricular end-diastolic volume (LVEDV) from baseline (V0) to the 360-day follow-up (V12), assessed by (a) cardiac magnetic resonance imaging (MRI) (n = 13 in placebo group, n = 14 in UC-MSCs group) and (b) echocardiography (n = 19 in placebo group, n = 18 in UC-MSCs group). P values were determined using independent t tests. Data are presented as mean ± SEM

Back to article page